Neoleukin Therapeutics Inc (NASDAQ: NGNE) stock enjoyed a major increase of 16.7% on 10/2/25. The shares closed at $20.98. Moreover, this advance was accompanied by exceptionally high trading volume at 360% of normal. Relative to the market the stock has been strong over the last nine months and has risen 21.6% during the last week.
Current PriceTarget Research Rating
Neoleukin Therapeutics has a current Value Trend Rating of C (High Neutral). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Neoleukin Therapeutics has a neutral Appreciation Score of 48 and a slightly positive Power Rating of 68, triggering the High Neutral Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment